Oncobiologics (NASDAQ:OTLK) Downgraded by Wall Street Zen to “Sell”

16 Aug 2026, 07:32 by Mitch Edgeman · The Markets Daily

Wall Street Zen downgraded shares of Oncobiologics (NASDAQ:OTLK – Free Report) from a hold rating to a sell rating in a research report released on Saturday.

OTLK has been the subject of several other research reports. Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. HC Wainwright raised their target price on shares of Oncobiologics to $1.60 and gave the company a “neutral” rating in a research note on Monday, July 27th. BTIG Research restated a “buy” rating and set a $4.00 price target on shares of Oncobiologics in a research report on Friday. Finally, Ascendiant Capital Markets upped their price target on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oncobiologics currently has an average rating of “Hold” and an average price target of $4.65.

Check Out Our Latest Report on OTLK

Oncobiologics Price Performance

OTLK opened at $0.76 on Friday. The stock has a market capitalization of $112.39 million, a PE ratio of -0.98 and a beta of 0.82. The firm’s fifty day moving average price is $1.31 and its 200 day moving average price is $0.70. Oncobiologics has a 12-month low of $0.16 and a 12-month high of $3.39.

Oncobiologics (NASDAQ:OTLK – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.97 million. On average, equities research analysts forecast that Oncobiologics will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Oncobiologics

In related news, Director Faisal Ghiath Sukhtian bought 95,398 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was purchased at an average price of $1.05 per share, with a total value of $100,167.90. Following the completion of the transaction, the director directly owned 220,972 shares of the company’s stock, valued at $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ghiath M. Sukhtian purchased 2,525,252 shares of the stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $2,499,999.48. Following the completion of the transaction, the director owned 24,617,320 shares of the company’s stock, valued at $24,371,146.80. The trade was a 11.43% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 11,189,359 shares of company stock valued at $7,662,666. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of OTLK. Russell Investments Group Ltd. lifted its stake in shares of Oncobiologics by 865.2% during the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after acquiring an additional 21,941 shares during the period. AQR Capital Management LLC increased its position in Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares during the last quarter. Institutional investors own 11.20% of the company’s stock.

Oncobiologics News Summary

Here are the key news stories impacting Oncobiologics this week:

Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $4.00 price target, implying significant potential upside from recent trading levels. Benzinga analyst rating report
Positive Sentiment: Management highlighted FDA approval of LYTENAVA, an ophthalmic bevacizumab product intended to address the U.S. wet age-related macular degeneration market. The approval could support future commercialization and revenue growth. Outlook Therapeutics third-quarter results and business update
Positive Sentiment: Director Ghiath M. Sukhtian purchased 2.53 million shares for approximately $2.5 million, increasing his direct ownership by 11.43%. The insider purchase may be viewed as a vote of confidence in the company’s prospects. SEC insider transaction filing
Neutral Sentiment: The company’s quarterly loss was $0.09 per share, compared with a $0.44 loss a year earlier, indicating year-over-year improvement but still missing the $0.08 consensus estimate. Zacks quarterly earnings report
Negative Sentiment: Revenue was only approximately $10,000, far below the $970,000 consensus estimate. The revenue shortfall reinforces concerns about the timing of LYTENAVA’s commercial ramp and near-term cash generation. MarketBeat earnings report
Negative Sentiment: Oncobiologics priced a $55 million public offering of 55.56 million shares at $0.99 each, along with immediately exercisable warrants carrying a $1.10 strike price. The large offering creates substantial dilution and likely contributed to selling pressure. Public offering announcement

Oncobiologics Company Profile

(Get Free Report)

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.